Huntingtin-Interacting Protein 1 Promotes Vpr-Induced G2 Arrest and HIV-1 Infection in Macrophages.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
19 11 2021
Historique:
received: 08 10 2021
revised: 02 11 2021
accepted: 17 11 2021
entrez: 27 11 2021
pubmed: 28 11 2021
medline: 15 2 2022
Statut: epublish

Résumé

Human immunodeficiency virus type 1 (HIV-1) modulates the host cell cycle. The HIV-1 accessory protein Vpr arrests the cell cycle at the G2 phase in dividing cells, and the ability of Vpr to induce G2 arrest is well conserved among primate lentiviruses. Additionally, Vpr-mediated G2 arrest likely correlates with enhanced HIV-1 infection in monocyte-derived macrophages. Here, we screened small-interfering RNA to reveal candidates that suppress Vpr-induced G2 arrest and identified Huntingtin-interacting protein 1 (HIP1) required for efficient G2 arrest. Interestingly, HIP1 was not essential for Vpr-induced DNA double-strand breaks, which are required for activation of the DNA-damage checkpoint and G2 arrest. Furthermore, HIP1 knockdown suppressed HIV-1 infection in monocyte-derived macrophages. This study identifies HIP1 as a factor promoting Vpr-induced G2 arrest and HIV-1 infection in macrophages.

Identifiants

pubmed: 34835114
pii: v13112308
doi: 10.3390/v13112308
pmc: PMC8624357
pii:
doi:

Substances chimiques

DNA-Binding Proteins 0
HIP1 protein, human 0
RNA, Small Interfering 0
vpr Gene Products, Human Immunodeficiency Virus 0
vpr protein, Human immunodeficiency virus 1 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

mBio. 2018 Oct 23;9(5):
pubmed: 30352932
Mol Cell. 2018 Jun 7;70(5):961-970.e5
pubmed: 29883611
Nat Med. 1997 Oct;3(10):1117-23
pubmed: 9334723
Proc Natl Acad Sci U S A. 2016 May 10;113(19):5311-6
pubmed: 27114546
PLoS One. 2016 Sep 20;11(9):e0163100
pubmed: 27648839
PLoS One. 2011;6(11):e27815
pubmed: 22110766
PLoS Pathog. 2013;9(12):e1003812
pubmed: 24339781
mBio. 2020 Aug 4;11(4):
pubmed: 32753492
Virol J. 2007 Jun 08;4:57
pubmed: 17559673
Virology. 2000 Oct 10;276(1):16-26
pubmed: 11021990
Proc Natl Acad Sci U S A. 2019 May 7;116(19):9568-9577
pubmed: 31019079
Cell. 2014 Jan 16;156(1-2):134-45
pubmed: 24412650
Cell Host Microbe. 2014 Dec 10;16(6):722-35
pubmed: 25464830
Biochemistry. 2004 Dec 14;43(49):15418-28
pubmed: 15581353
mBio. 2019 Aug 20;10(4):
pubmed: 31431548
Nat Med. 1998 Jan;4(1):65-71
pubmed: 9427608
Viruses. 2020 Jan 15;12(1):
pubmed: 31952107
Nature. 2011 Dec 21;481(7381):365-70
pubmed: 22190034
Science. 1997 Jun 20;276(5320):1857-61
pubmed: 9188531
J Biol Chem. 2007 Mar 9;282(10):7287-98
pubmed: 17210576
J Virol. 2005 Mar;79(6):3557-64
pubmed: 15731250
J Virol. 2000 Jul;74(13):6058-67
pubmed: 10846089
J Virol. 2007 Sep;81(17):8878-90
pubmed: 17553871
Biochem Biophys Res Commun. 1997 Mar 17;232(2):550-4
pubmed: 9125220
Elife. 2020 Jun 15;9:
pubmed: 32538781
Cancer Cell Int. 2009 Aug 12;9:20
pubmed: 19674438
J Biol Chem. 2007 Sep 14;282(37):27046-27057
pubmed: 17620334
J Exp Med. 1998 Apr 6;187(7):1103-11
pubmed: 9529326
Mol Cell Biol. 2004 Nov;24(21):9286-94
pubmed: 15485898
PLoS Pathog. 2010 Sep 02;6(9):e1001080
pubmed: 20824083
Cancer Cell. 2003 May;3(5):471-82
pubmed: 12781365
J Virol. 1995 Feb;69(2):882-8
pubmed: 7815556
J Mol Biol. 2016 Jul 3;428(13):2744-57
pubmed: 27181198
J Virol. 1995 Oct;69(10):6304-13
pubmed: 7666531
Hum Mol Genet. 2001 Aug 15;10(17):1807-17
pubmed: 11532990
J Virol. 1997 May;71(5):3961-71
pubmed: 9094673
PLoS One. 2014 Jan 22;9(1):e86840
pubmed: 24466265
J Neurosci Res. 2005 Jul 1;81(1):62-72
pubmed: 15906374
Biochem Biophys Res Commun. 2007 Aug 3;359(3):729-34
pubmed: 17560945
J Virol. 2015 Jan;89(1):230-40
pubmed: 25320300
Nature. 2000 Nov 23;408(6811):433-9
pubmed: 11100718
Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11778-83
pubmed: 17609381
J Biol Chem. 2001 Dec 7;276(49):46230-6
pubmed: 11577110
J Clin Invest. 2002 Aug;110(3):351-60
pubmed: 12163454
Curr HIV Res. 2009 Mar;7(2):163-8
pubmed: 19275585
Microbes Infect. 2007 Apr;9(4):490-7
pubmed: 17347016
J Biol Chem. 2001 Oct 19;276(42):39271-6
pubmed: 11517213
Cell Cycle. 2007 Jan 15;6(2):182-8
pubmed: 17314515
J Virol. 2006 Nov;80(21):10407-18
pubmed: 16956949
Microbes Infect. 2005 Jul;7(9-10):1150-60
pubmed: 15908254
J Virol. 2007 May;81(10):5284-93
pubmed: 17344301
mBio. 2016 Sep 13;7(5):
pubmed: 27624129
Virology. 2016 Sep;496:194-202
pubmed: 27343732
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4130-5
pubmed: 17360488
J Virol. 1996 Apr;70(4):2516-24
pubmed: 8642681
J Virol. 1997 Jun;71(6):4331-8
pubmed: 9151821
Cell Rep. 2016 Oct 4;17(2):413-424
pubmed: 27705790
EMBO J. 1998 Feb 16;17(4):909-17
pubmed: 9463369
Viruses. 2020 Mar 23;12(3):
pubmed: 32210193
Genomics. 1997 Dec 1;46(2):313-5
pubmed: 9417924
FEBS Lett. 2006 Oct 2;580(22):5275-82
pubmed: 16979168
PLoS Pathog. 2007 Jul;3(7):e85
pubmed: 17630831
Cell Host Microbe. 2016 Mar 9;19(3):304-10
pubmed: 26962941
Nat Genet. 1997 May;16(1):44-53
pubmed: 9140394
Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):E3921-30
pubmed: 27335459
J Virol. 2010 Apr;84(7):3320-30
pubmed: 20089662

Auteurs

Tomoyuki Murakami (T)

Viral Infectious Diseases Unit, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.

Ryosuke Matsuura (R)

Viral Infectious Diseases Unit, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.
Laboratory of Global Infectious Diseases Control Science, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.

Nopporn Chutiwitoonchai (N)

Viral Infectious Diseases Unit, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.

Masami Takei (M)

Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi, Kami-cho, Itabashi, Tokyo 173-8610, Japan.

Yoko Aida (Y)

Viral Infectious Diseases Unit, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.
Laboratory of Global Infectious Diseases Control Science, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH